KARA BARHAM: Open Payments
NPI 1568957439 · HATTIESBURG, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,018 in 63 payments from 14 companies in 2025. Trend: 2023 $1,726 · 2024 $1,356 · 2025 $1,018
Food & beverage: $1,018
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 21 | $235 |
| Axsome Therapeutics, Inc. | 8 | $162 |
| Novo Nordisk Inc | 10 | $148 |
| Amgen Inc. | 5 | $83 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $66 |
| PFIZER INC. | 3 | $64 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $58 |
| Lilly USA, LLC | 3 | $55 |
| Corium, LLC | 2 | $37 |
| Phathom Pharmaceuticals, Inc. | 1 | $31 |
Products named: Auvelity, VRAYLAR, QULIPTA, XIFAXAN, Ozempic, Rybelsus, TRINTELLIX, OTEZLA.
Industry payments across MS — which companies pay providers there.
